Meeting
2019 ASCO Annual Meeting
First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid tumors.
Authors
Toshio Shimizu
Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
Toshio Shimizu , Yutaka Fujiwara , Kan Yonemori , Takafumi Koyama , Akihiko Shimomura , Kenji Tamura , Satoru Iwasa , Jun Sato , Shigehisa Kitano , Hiroki Ikezawa , Maiko Nomoto , Ryo Nakajima , Takuma Miura , Noboru Yamamoto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03386942
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5544)
DOI
10.1200/JCO.2019.37.15_suppl.5544
Abstract #
5544
Poster Bd #
367
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial.
First Author: Shin Nishio
Poster
2019 ASCO Annual Meeting
A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.
First Author: Patrick Schoffski
Poster
2016 ASCO Annual Meeting
Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours.
First Author: Samuel John Harris
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang